NCT04539301招募中不适用
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 2,100
- 试验地点
- 1
- 主要终点
- Agreement between measured and estimated levels of each factor-Xa inhibitor
研究概览
简要总结
Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Agreement between measured and estimated levels of each factor-Xa inhibitor
时间窗: 2 years
An estimated anticoagulant level between 80 and 120% of the value obtained by the reference method ("specific assay") will be deemed clinically acceptable, i.e. the patient's management would have been the same.
次要结局
- Evaluation of the performance of the estimated anticoagulant level method by an inter-laboratory comparison program(2 years)
- Cost comparison (estimated anticoagulant level method versus specific dosage)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Predicting Outcomes in ICH Patients on Direct Factor Xa InhibitorsIntra Cerebral HemorrhageNCT06383741Insel Gruppe AG, University Hospital Bern200
已完成
不适用
Reduction of Heparin Dose in Dialysis With Evodial SystemChronic Kidney FailureNCT00781690Vantive Health LLC53
已完成
2 期
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelAcute Ischemic StrokeTransient Ischemic Attack (TIA)NCT03766581Bristol-Myers Squibb2,366
已完成
4 期
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery DiseaseCoronary Artery DiseaseNCT04006288University of Florida90
已完成
3 期
A Study Investigating Treatment Factor X in People With Factor X DeficiencyFactor X DeficiencyNCT00930176Bio Products Laboratory16